Results 81 to 90 of about 923 (130)

Masthead: (View 3/2025)

VIEW, Volume 6, Issue 3, June 2025.
wiley   +1 more source

The first Chinese oral anti-COVID-19 drug Azvudine launched

The Innovation, 2022
Bin Yu, Junbiao Chang
openaire   +2 more sources

Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients [PDF]

, 2021
Jinlan Zhang, Yuhuan Li, Lulu Wang, Hongqi Liu, Shuaiyao Lu, Yong Liu, Ke Li, Bin Liu, Suyun Li, Fengmin Shao, Kun Wang, Ning Sheng, Rui Li, Jin‐Jin Cui, Peichun Sun, Chunxia Ma, Bo Zhu, Zhe Wang, Yuan-Hao Wan, Shi‐Shan Yu, Yongsheng Che, Chaoyang Wang, Chen Wang, Qiangqian Zhang, Limin Zhao, Xiaozhong Peng, Zhenshun Cheng, Junbiao Chang, Jian‐Dong Jiang   +28 more
openalex   +1 more source

Masthead: (View 2/2025)

VIEW, Volume 6, Issue 2, April 2025.
wiley   +1 more source

Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study

Journal of Infection and Public Health
Background: COVID-19 pneumonia has spread across China and globally since late 2019, becoming a pandemic. Its extremely contagious nature as well as high morbidity and mortality rates have attracted widespread attention globally.
Wei Yang, Weiting Zhang, Jing Zhou, Xinyue Ma, Changsong Wang, Mingyan Zhao, Kaijiang Yu   +6 more
doaj   +1 more source

Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19

Journal of Infection, 2023
Yuan Gao, Zujin Luo, Shan Ren, Zhonghui Duan, Ying Han, Huihang Liu, Ziwen Gao, Xinyu Zhang, Zhongjie Hu, Yingmin Ma   +9 more
openaire   +2 more sources

Azvudine and nirmatrelvir–ritonavir in hospitalized patients with moderate‐to‐severe COVID‐19: Emulation of a randomized target trial [PDF]

, 2023
Yiling Zhou, Yi Liu, Li Jiang, Renqing Zhang, Huohuo Zhang, Qingyang Shi, Zhirong Yang, Yi Mao, Sha Liu, Zhibo Yang, Jialin Ding, Yongzhao Zhou, Bi Ren, Liping He, Xing Zhao, Weimin Li, Sheyu Li, Dan Liu   +17 more
openalex   +1 more source

Molecular mechanism of azvudine in the treatment of COVID-19 based on network pharmacology and molecular docking

, 2023
Ning Tang, Yan Wang, Yu-Meng Han, Yang Zhao, Jia-Rui Miao, Bing Li   +5 more
openalex   +1 more source

Efficacy of Azvudine Therapy in Patients with Severe and Non-Severe COVID‐19: A Propensity Score-Matched Analysis

Infection and Drug Resistance
Siqin Zhang,1,* Songsong Tan,1,* Bin Yang,2 Yaoyao Wu,3 Guohang Yuan,3 Fengjiao Chen,4 Lin Liu3,5 1Department of Endocrinology and Metabolism, Guizhou Provincial People’s Hospital, Guiyang, Guizhou, 550002, People’s Republic of China; 2Department
Zhang S, Tan S, Yang B, Wu Y, Yuan G, Chen F, Liu L   +6 more
doaj  

Risk of severe case in COVID-19 patients and Azvudine: A Retrospective cohort study after exit from ‘zero-COVID’ policy [PDF]

Lishan Li, Li Li, Lihua Ye, Baijie Lu, Jieling Wang, Guanhua Wei, Zhuang Bian   +6 more
openalex   +1 more source